OCTIMET oncology was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen.
Headed by Dr. Timothy Perera (CEO), OCTIMET has licensed highly selective MET kinase inhibitors with clean safety profiles from Janssen Pharmaceutica and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents using biomarker defined intelligent patient selection.
Company Details
- Address
- Beerse
- Phone
- 32473558353
- bd****@****met.com
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- octimet.com
- Keywords
- Follow.
- HQ
- Beerse
Octimet Oncology Nv Questions
Octimet Oncology Nv's helpline number is 32473558353
Octimet Oncology Nv's website is octimet.com
Octimet Oncology Nv's LinkedIn profile is https://be.linkedin.com/company/octimet-oncology-nv
Octimet Oncology Nv's industry is
Research Services
Octimet Oncology Nv's top competitors are
Ohmx.bio,
Sequana Medical Nv,
Institute For Biomedical Entrepreneurship, Inc. (Ibe, Inc.),
Cantoni Therapeutics,
Ardena,
Ermium Therapeutics,
Flamingo Therapeutics,
Myneo Therapeutics,
Confo Therapeutics,
Protealis.
Octimet Oncology Nv's support email address is bd@octimet.com
Octimet Oncology Nv's categories are Research Services
